Dyrenium and Pregnancy
At this time, no clinical studies have been conducted on the association between Dyrenium and pregnancy. However, evidence suggests that the drug may block the effects of folic acid, which is necessary for fetal development. Since the medicine may potentially cause harm to an unborn child, notify your healthcare provider immediately if you are taking Dyrenium and pregnancy occurs.
Dyrenium® (triamterene) is a pregnancy Category C medicine, meaning that it could potentially cause harm to your unborn child.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in humans but that do show side effects to the fetus in animal studies. Pregnancy Category C is also given to medicines that have not been studied in either pregnant women or animals. A pregnancy Category C medicine may still be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh the possible risks to the unborn child.
Dyrenium has not been studied in pregnant animals or humans. However, similar medications have not caused problems in pregnant animals. It is important to note, however, that animals do not always respond to medicines the same way that humans do. In fact, there is some evidence that Dyrenium can block the effects of folic acid (which is necessary for fetal development). Therefore, the medication may be prescribed only if the healthcare provider believes that the benefits to the pregnant woman outweigh the risks to the unborn child.
Generally, Dyrenium should be used in pregnant women only when absolutely necessary. It typically is not used to treat high blood pressure during pregnancy.